Dyne Therapeutics Inc. shares surged more than 40% after people with knowledge of the matter said the developer of drugs to treat muscle diseases has received takeover interest from larger pharmaceutical companies. The Waltham, Massachusetts-based company has been speaking with advisers as it considers options including a possible sale or partnership, according to the people, who asked not to be identified discussing confidential information.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.54 USD | -1.56% | -0.86% | +94.40% |
02/05 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
30/04 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.40% | 2.27B | |
+24.05% | 47.02B | |
+49.73% | 41.86B | |
+0.25% | 41.76B | |
-4.27% | 28.8B | |
+12.70% | 26.05B | |
-21.27% | 19.15B | |
+4.00% | 12.55B | |
+31.50% | 12.34B | |
-3.77% | 11.82B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Dyne Therapeutics Reportedly Seeing Takeover Interest, Weighing Options